Dengue vaccine development: challenges and prospects
Purpose of review - Dengue vaccine development is a high public health priority. To date, no dengue vaccine is in widespread use. Here we review the challenges in dengue development and the latest results for the second-generation dengue vaccines. - Recent findings - The biggest hurdle is th...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2022
|
| In: |
Current opinion in infectious diseases
Year: 2022, Jahrgang: 35, Heft: 5, Pages: 390-396 |
| ISSN: | 1473-6527 |
| DOI: | 10.1097/QCO.0000000000000871 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1097/QCO.0000000000000871 Verlag, lizenzpflichtig, Volltext: https://journals.lww.com/co-infectiousdiseases/Abstract/2022/10000/Dengue_vaccine_development__challenges_and.4.aspx 
|
| Verfasserangaben: | Annelies Wilder-Smith |
MARC
| LEADER | 00000caa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1818573334 | ||
| 003 | DE-627 | ||
| 005 | 20240326080203.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221011s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/QCO.0000000000000871 |2 doi | |
| 035 | |a (DE-627)1818573334 | ||
| 035 | |a (DE-599)KXP1818573334 | ||
| 035 | |a (OCoLC)1361695829 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Wilder-Smith, Annelies |e VerfasserIn |0 (DE-588)1064971458 |0 (DE-627)815377339 |0 (DE-576)186940998 |4 aut | |
| 245 | 1 | 0 | |a Dengue vaccine development |b challenges and prospects |c Annelies Wilder-Smith |
| 264 | 1 | |c 2022 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 11.10.2022 | ||
| 520 | |a Purpose of review - Dengue vaccine development is a high public health priority. To date, no dengue vaccine is in widespread use. Here we review the challenges in dengue development and the latest results for the second-generation dengue vaccines. - Recent findings - The biggest hurdle is the immunological interaction between the four antigenically distinct dengue serotypes. The advantages of second-generation dengue vaccines are the inclusion of nonstructural proteins of the dengue backbone and a more convenient dosing with reduced numbers of doses needed. - Summary - Although dengue-primed individuals can already benefit from vaccination with the first licensed dengue vaccine CYD-TDV, the public health need for the dengue-naive population has not yet been met. The urgent need remains to identify correlates of both protection and enhancement; until such correlates have been identified, all second-generation dengue vaccines still need to go through full phase 3 trials. The 5-year efficacy and safety data for both second-generation dengue vaccines are imminent. | ||
| 773 | 0 | 8 | |i Enthalten in |t Current opinion in infectious diseases |d London : Lippincott Williams & Wilkins, 1988 |g 35(2022), 5, Seite 390-396 |h Online-Ressource |w (DE-627)32445595X |w (DE-600)2026993-6 |w (DE-576)093981171 |x 1473-6527 |7 nnas |a Dengue vaccine development challenges and prospects |
| 773 | 1 | 8 | |g volume:35 |g year:2022 |g number:5 |g pages:390-396 |g extent:7 |a Dengue vaccine development challenges and prospects |
| 856 | 4 | 0 | |u https://doi.org/10.1097/QCO.0000000000000871 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://journals.lww.com/co-infectiousdiseases/Abstract/2022/10000/Dengue_vaccine_development__challenges_and.4.aspx |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20221011 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 1064971458 |a Wilder-Smith, Annelies |m 1064971458:Wilder-Smith, Annelies |d 910000 |d 912800 |d 50000 |e 910000PW1064971458 |e 912800PW1064971458 |e 50000PW1064971458 |k 0/910000/ |k 1/910000/912800/ |k 0/50000/ |p 1 |x j |y j | ||
| 999 | |a KXP-PPN1818573334 |e 4196037550 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"origin":[{"publisherPlace":"London ; [Erscheinungsort nicht ermittelbar]","dateIssuedDisp":"1988-","publisher":"Lippincott Williams & Wilkins ; Ovid","dateIssuedKey":"1988"}],"id":{"issn":["1473-6527","1535-3877"],"zdb":["2026993-6"],"eki":["32445595X"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Current opinion in infectious diseases","title":"Current opinion in infectious diseases"}],"pubHistory":["1.1988 -"],"part":{"year":"2022","issue":"5","pages":"390-396","volume":"35","text":"35(2022), 5, Seite 390-396","extent":"7"},"note":["Gesehen am 29.01.03"],"disp":"Dengue vaccine development challenges and prospectsCurrent opinion in infectious diseases","type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"recId":"32445595X"}],"physDesc":[{"extent":"7 S."}],"name":{"displayForm":["Annelies Wilder-Smith"]},"id":{"eki":["1818573334"],"doi":["10.1097/QCO.0000000000000871"]},"origin":[{"dateIssuedDisp":"2022","dateIssuedKey":"2022"}],"recId":"1818573334","language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 11.10.2022"],"person":[{"role":"aut","roleDisplay":"VerfasserIn","display":"Wilder-Smith, Annelies","given":"Annelies","family":"Wilder-Smith"}],"title":[{"title":"Dengue vaccine development","subtitle":"challenges and prospects","title_sort":"Dengue vaccine development"}]} | ||
| SRT | |a WILDERSMITDENGUEVACC2022 | ||